Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Lisa Leypoldt

Lisa Leypoldt

University Medical Center Hamburg
Considering PRO assessments in multiple myeloma to capture AEs of novel therapies 1:19
Considering PRO assessments in multiple myeloma to capture AEs of novel therapies
Lisa Leypoldt • 18 Sep 2025
Cytogenetic subgroup analyses from the Phase II GMMG-CONCEPT trial of Isa-KRd in NDMM 1:48
Cytogenetic subgroup analyses from the Phase II GMMG-CONCEPT trial of Isa-KRd in NDMM
Lisa Leypoldt • 18 Sep 2025
Managing cardiovascular toxicities associated with carfilzomib in multiple myeloma 1:41
Managing cardiovascular toxicities associated with carfilzomib in multiple myeloma
Lisa Leypoldt • 18 Sep 2025
Patient preferences at the time of relapse in multiple myeloma 1:22
Patient preferences at the time of relapse in multiple myeloma
Lisa Leypoldt • 18 Sep 2025
Association of cardiac biomarkers and AEs with carfilzomib-containing regimens for high-risk NDMM 2:49
Association of cardiac biomarkers and AEs with carfilzomib-containing regimens for high-risk NDMM
Lisa Leypoldt • 27 Sep 2024
Debate: anti-CD38-VRd quads versus anti-CD38-KRd quads in newly diagnosed myeloma 1:20
Debate: anti-CD38-VRd quads versus anti-CD38-KRd quads in newly diagnosed myeloma
Lisa Leypoldt • 27 Sep 2024
Four-year follow-up of GMMG-CONCEPT: efficacy of Isa-KRd in high-risk newly diagnosed myeloma 1:27
Four-year follow-up of GMMG-CONCEPT: efficacy of Isa-KRd in high-risk newly diagnosed myeloma
Lisa Leypoldt • 27 Sep 2024
The management of triple-class refractory myeloma in the absence of immunotherapies 2:05
The management of triple-class refractory myeloma in the absence of immunotherapies
Lisa Leypoldt • 5 Jun 2024
XPO1 inhibition with selinexor for RRMM 2:00
XPO1 inhibition with selinexor for RRMM
Lisa Leypoldt • 5 Jun 2024
Advancements in clinical trials for high-risk newly diagnosed multiple myeloma 2:07
Advancements in clinical trials for high-risk newly diagnosed multiple myeloma
Lisa Leypoldt • 4 Jun 2024
GMMG-DANTE: DVd in patients with multiple myeloma and renal impairment 1:08
GMMG-DANTE: DVd in patients with multiple myeloma and renal impairment
Lisa Leypoldt • 29 Sep 2023
Clinical trials exploring treatment approaches for high-risk NDMM 1:50
Clinical trials exploring treatment approaches for high-risk NDMM
Lisa Leypoldt • 29 Sep 2023
GMMG-CONCEPT trial: Isa-KRd in high-risk newly diagnosed multiple myeloma 2:08
GMMG-CONCEPT trial: Isa-KRd in high-risk newly diagnosed multiple myeloma
Lisa Leypoldt • 29 Sep 2023
The content of VJHemOnc is intended for healthcare professionals